Janux Therapeutics, Inc. Common Stock (JANX) is a publicly traded Healthcare sector company. As of October 25, 2026, JANX trades at $16.65 with a market cap of $1.02B and a P/E ratio of -10.33. JANX moved -2.40% today. Year to date, JANX is +22.05%; over the trailing twelve months it is -31.89%. Its 52-week range spans $12.12 to $35.34. Analyst consensus is strong buy with an average price target of $33.40. Rallies surfaces JANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for JANX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $16.65 |
| Market Cap | $1.02B |
| P/E Ratio | -10.33 |
| EPS | $-1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $35.34 |
| 52-Week Low | $12.12 |
| Volume | 286.08K |
| Avg Volume | 0 |
| Revenue (TTM) | $24.00M |
| Net Income | $-102.59M |
| Gross Margin | 0.00% |
11 analysts cover JANX: 0 strong buy, 10 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.40.